Antengene Corp., a hematology and oncology-focused biopharmaceutical company, has closed $97 million in Series C financing to support continued clinical development of its pipeline of hematology and oncology therapies, expanding in-house R&D capabilities and commercial infrastructures in APAC markets. Antengene has a pipeline of six clinical-stage programs and six preclinical stage oncology assets: ATG-010 (selinexor) is the first and only oral selective inhibitor of nuclear export (SINE...